ClinicalTrials.gg
CompletedNCT05519514Updated Aug 29, 2022

Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects

A Phase 1 interventional study of Cortiment and Budesonide in Healthy Subjects, Human Volunteers and Healthy Participants, sponsored by Abbott. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-29.

Sponsored by Abbott · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jul 2021, registered Jul 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A randomized, open label, single dose, balanced, two treatment, two sequence, four period, fully replicate, cross over bioequivalence study under fasting condition.

02

Conditions studied

  • Healthy Subjects
  • Human Volunteers
  • Healthy Participants
  • Bioequivalence

Keywords

  • Bioequivalence
  • Budesonide prolonged release tablets 9 mg
  • Pharmacokinetic
  • fully replicate
03

In context

Lead sponsor

Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Normal healthy human adult male and non- pregnant female volunteers between 18-45 years (both ages inclusive) of age.
  2. Who is given written and are willing to participate in the study.
  3. of 18.50 to 30.00 Kg/m2 (both inclusive).
  4. No evidence of underlying disease during the pre-study screening, medical history, physical examination and laboratory investigations performed within 21 days prior to commencement of the study.
  5. Pre-study screening laboratory tests are either normal or within acceptable limits or are considered by the Investigator to be of no clinical significance with respect to participation in the study.
  6. Negative test results for alcohol (in breath or in urine) and urine drugs of abuse.
  7. Who is negative or non-reactive for antibodies to 1 and 2, \& C and Rapid Plasma Reagin.
  8. 12 lead recording within normal or within acceptable limits or as considered by the Investigator to be of no clinical significance with respect to his/ her participation in the study.
  9. Normal or not chest X-ray (PA) taken within 06 months before the day of dosing.
  10. Who will be available for the entire study period and is capable of understanding and communicating with the investigators and clinical study facility staff.
  11. Female volunteers who are having negative results in urine pregnancy test during screening and negative Beta hCG-test at the time of check-in.
  12. Females with must agree to use an acceptable method of at least 2 days prior to dosing of IP, during the study \& for 03 days following their last dose of IP.
  13. Male subjects and/or Female subject's partner must agree to use condoms, vasectomy or spermicide in addition to female contraception for additional protection against conception throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Known history of / allergic to Budesonide or any component of the formulation and/or to any other related drug.
  2. History or presence of significant cardiovascular, respiratory, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease and .
  3. Female volunteers who are:

    • Nursing mothers.
    • Positive result in beta hCG test.
    • Lactating women (currently breast feeding).
    • Female subjects not confirming to using measures, from the date of screening until the completion of the study. Abstinence, barrier methods (condom, diaphragm, etc.) are acceptable.
    • Using hormonal contraceptives either oral or implants.
  4. History/presence of significant alcohol dependence (abuse) or drug abuse within the past 1year, current alcohol abuse (> 5 units/week, 1 unit= 10 mL or 8 g of pure alcohol) or suspected abuse.
  5. Everyday smoker (who has smoked at least 100 cigarettes in her lifetime, and who now smokes every day) or consumption of tobacco products.
  6. History/presence of Asthma.
  7. History/presence of urticaria or other allergic type reactions after taking any medication.
  8. History/presence of illness within 04 weeks before the start of the study.
  9. History/presence of significant Hypersensitivity to heparin.
  10. History of clinically relevant allergy (except for untreated, asymptomatic, seasonal allergies at time of dosing) or any allergic reactions to any drugs.
  11. Who is scheduled for surgery any time during study or within 03 days after study completion.
  12. History of difficulty in donating blood.
  13. Who has unsuitable veins for repeated vein puncture. Who is participating in any other clinical or bioequivalence study or otherwise would have donated in excess of 350 mL of blood in the last 90 days.
  1. Who has taken prescription medication or OTC products (including vitamins and natural products) within 14 days prior to dosing of IP in Period 1, including topical medication. 16. Who was hospitalized within 28 days prior to administration of the study medication. 17. History of difficulty in swallowing. 18. Evidence of skin lesions on forearm of signs of vein puncture on the forearm suggestive of recent donation or participation in clinical trial. 19. Who has Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the Investigator. 20. Who has Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the Investigator. 21. Who is tested positive for COVID-19 test.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Active comparator
    Cortiment (Budesonide 9 mg prolonged release tablet)

    Drug: Cortiment

  • Experimental
    Budesonide 9 mg prolonged release tablet

    Drug: Budesonide

Interventions

  • Budesonide 9 mg prolonged release tablets

  • Experimental (Budesonide 9 mg prolonged release tablets)

06

What researchers measure

Primary outcomes

  1. Bioequivalence of Test Product (T) Vs Reference Product (R) Pharmacokinetic parameters: Cmax (Maximum plasma concentration)

    Cmax (Maximum plasma concentration)

    Time frame: Till 72 hours post dose after each dosing

  2. Bioequivalence of Test Product (T) Vs Reference Product (R) Pharmacokinetic Parameters: AUC0-t (area under the curve)

    AUC0-t (area under the curve)

    Time frame: Till 72 hours post dose after each dosing

Secondary outcomes

  1. Safety and tolerability of Test Product (T) and the Reference Product (R) Serious adverse events

    Incidences of Serious Adverse events

    Time frame: Till 30 days since last dosing period

  2. Safety and tolerability of Test Product (T) and the Reference Product (R) Systolic and diastolic blood pressure

    Vital Signs assessment in terms of: Systolic and diastolic blood pressure measured as mm of Hg.

    Time frame: Till 72 hours post dose after each dosing

  3. Safety and tolerability of Test Product (T) and the Reference Product (R) Pulse rate

    Vital Signs assessment in terms of: Pulse rate measured as bpm.

    Time frame: Till 72 hours post dose after each dosing

  4. Safety and tolerability of Test Product (T) and the Reference Product (R) Oral temperature

    Vital Signs assessment in terms of: Oral temperature measured as degree fahrenheit (°F).

    Time frame: Till 72 hours post dose after each dosing

  5. Safety and tolerability of Test Product (T) and the Reference Product (R) Wellbeing assessment: Wellbeing assessment by questioning the subjects about their health status.

    Wellbeing assessment will be done as per the study site's applicable standard operating procedure, initially subjects wellbeing is recorded in "wellbeing form" by asking general questions like "How do you feel?", how are you feeling since last asked?. Further, overall subject response is then transcribed into the subject study CRF as below: Is overall wellbeing of the Volunteer Satisfactory? Satisfactory / Not satisfactory If it is not satisfactory, the same is treated as AE and is recorded in applicable AE form as per process.

    Time frame: Till 72 hours post dose after each dosing

  6. Safety and tolerability of Test Product (T) and the Reference Product (R) adverse events

    Incidences of adverse events

    Time frame: Till 21 days from AE occurence

  7. Safety and tolerability of Test Product (T) and the Reference Product (R) abnormal laboratory values

    No of subjects with abnormal laboratory values. Lab values for hematology, biochemistry and urine analysis

    Time frame: Till 21 days from AE occurence

07

Study locations

1 site
  • Study Site
    Mangalore, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Aug 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2022
First posted
Aug 29, 2022
StartActual
Jul 12, 2021
Primary completionActual
Aug 8, 2021
CompletionActual
Nov 15, 2021
Last update
Aug 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05519514
Lead sponsor
Abbott
Responsible party
Sponsor
First posted
Aug 29, 2022
Start date
Jul 12, 2021
Primary completion
Aug 8, 2021
Completion
Nov 15, 2021
Last update
Aug 29, 2022

Study contacts

Dr. Shivani Acharya, MD pharmacology
study director · Abbott

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion